Nasopharyngeal cancer (NPC) around the Mediterranean area: Standard of care

Abstract Mediterranean area (MA) represents a zone of intermediate incidence (1–5/100,000) for NPC, the highest frequency being observed in North Africa (NA) where it is characterized by a bimodal age repartition due to a first adolescence peak. In MA and NA, NPC remain diagnosed at advanced stages...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2012-12, Vol.84, p.e106-e109
Main Authors: Boussen, Hamouda, Ghorbal, Lilia, Naouel, Lejri, Bouaouina, Noureddine, Gritli, Said, Benna, Farouk, Daoud, Jamel
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Carcinoma
Chemoradiotherapy - methods
Chemotherapy
Concomitant
Disease-free survival
Epidemiology
Hematology, Oncology and Palliative Medicine
Humans
Mediterranean Region - epidemiology
Mediterreanean area
Nasopharyngeal
Nasopharyngeal Neoplasms - drug therapy
Nasopharyngeal Neoplasms - epidemiology
Nasopharyngeal Neoplasms - pathology
Nasopharyngeal Neoplasms - radiotherapy
Nasopharynx - drug effects
Nasopharynx - pathology
Nasopharynx - radiation effects
Overall
Prognosis
Radiotherapy
Standard of Care
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Mediterranean area (MA) represents a zone of intermediate incidence (1–5/100,000) for NPC, the highest frequency being observed in North Africa (NA) where it is characterized by a bimodal age repartition due to a first adolescence peak. In MA and NA, NPC remain diagnosed at advanced stages which impact poorly on overall and disease-free survival. It's therapy in MA followed the progresses and standardisation of protocols, based on concomitant chemoradiotherapy (CCRT) alone or preceeded by induction chemotherapy (ICT) in advanced (N2–3, T3–4) stages, while localized cases are managed irradiation alone. NPC overall an disease-free survival improved, due to the use of combined chemo and radiotherapy.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2010.09.005